Literature DB >> 17881650

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

Hugues de Lavallade, Jamshid S Khorashad, Howard P Davis, Dragana Milojkovic, Jaspal S Kaeda, John M Goldman, Jane F Apperley, David Marin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17881650     DOI： 10.1182/blood-2007-06-094508

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

Authors:  Franck E Nicolini; Amr R Ibrahim; Simona Soverini; Giovanni Martinelli; Martin C Müller; Andreas Hochhaus; Inge H Dufva; Dong-Wook Kim; Jorge Cortes; Michael J Mauro; Charles Chuah; Hélène Labussière; Stéphane Morisset; Catherine Roche-Lestienne; Eric Lippert; Sandrine Hayette; Senaka Peter; Wei Zhou; Véronique Maguer-Satta; Mauricette Michallet; John Goldman; Jane F Apperley; François-Xavier Mahon; David Marin; Gabriel Etienne
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

2.  Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.

Authors:  Sailaja Kagita; Srihari Uppalapati; Sangeeta Jiwatani; Vijay Gandhi Linga; Sadasivudu Gundeti; Narayana Nagesh; Raghunadharao Digumarti
Journal:  Tumour Biol       Date:  2014-04-26

3.  Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.

Authors:  Hidehiro Itonaga; Hideki Tsushima; Tomoko Hata; Emi Matsuo; Daisuke Imanishi; Yoshitaka Imaizumi; Yasuhisa Kawaguchi; Takuya Fukushima; Yuko Doi; Sayaka Mori; Shimeru Kamihira; Masao Tomonaga; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2012-01-20       Impact factor: 2.490

Review 4.  Selection of therapy: rational decisions based on molecular events.

Authors:  Jamshid S Khorashad; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

5.  Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Authors:  Franck Emmanuel Nicolini; Grzegorz W Basak; Simona Soverini; Giovanni Martinelli; Michael J Mauro; Martin C Müller; Andreas Hochhaus; Charles Chuah; Inge H Dufva; Giovanna Rege-Cambrin; Giuseppe Saglio; Mauricette Michallet; Hélène Labussière; Stéphane Morisset; Sandrine Hayette; Gabriel Etienne; Eduardo Olavarria; Wei Zhou; Senaka Peter; Jane F Apperley; Jorge Cortes
Journal:  Blood       Date:  2011-09-16       Impact factor: 22.113

6.  Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.

Authors:  Melanie R Bui; Victoria Hodson; Tom King; Derek Leopold; Shaodong Dai; Valerie Fiolkoski; Sarah Oakes; Richard Duke; David Apelian; Alex Franzusoff; James DeGregori
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

Review 7.  Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-20

8.  Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.

Authors:  C Cameron Yin; Jorge Cortes; John Galbincea; Neelima Reddy; Megan Breeden; Elias Jabbour; Rajyalakshmi Luthra; Dan Jones
Journal:  Cancer Sci       Date:  2010-09       Impact factor: 6.716

9.  Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.

Authors:  Efstratios Katsoulidis; Antonella Sassano; Beata Majchrzak-Kita; Nathalie Carayol; Patrick Yoon; Alison Jordan; Brian J Druker; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

10.  Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.

Authors:  Jorge E Cortes; Franck E Nicolini; Meir Wetzler; Jeffrey H Lipton; Luke Akard; Adam Craig; Nisha Nanda; Annie-Claude Benichou; Janis Leonoudakis; H Jean Khoury; Andreas Hochhaus; Michele Baccarani; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.